Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$2.13 ▲ +0.12
(+5.97%)
MKT CAP: $50.7M • VOL: 23.2K
52W L $2 52W H $12
KLRS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$46.2M | -$51.7M | -$199.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$43.4M | -$69.2M | -$190.4M |
| EBITDA (Normalized) | -$46.0M | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$38.4M | -$20.7M | -$124.5M |
| Capital Expenditures (CapEx) | $200.0K | — | — |
| Free Cash Flow (FCF) | -$38.6M | -$20.7M | -$124.5M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $98.1M | $1.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $78.8M | -$96.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR KLRS.